In 2019, Abyss Ingredients decided to move further in its study and led a second preclinical study on Peptidyss® to evaluate its anti-stress benefits on everyday life stress situations.
This new study was conducted on mice model, submitted to a moderate acute stress. Peptidyss® or control were orally administered every day for one week before the test. Corticosterone secretion, the equivalent of cortisol in humans, was followed at different time periods after the stress.
Abyss Ingredients latest study reveals that Peptidyss® supplementation at 300 mg/kg (mice dose) significantly reduces the corticosterone secretion when it is at the highest level (30 min after the stress), compared to the control group. This suggests that Peptidyss® helps to prevent the deleterious effects of high corticosterone level and to assure a faster back-to-normal of homeostasis.
In light of these new encouraging results, Abyss Ingredients will continue its research by enlarging its knowledge about the stress response system and its mechanisms thanks to the genetic expression.
This study is part of one of our long-term scientific programs VIPP project, which is dedicated to the identification and characterization of bioactive peptides, in this case for stress management application.